MCID: CYT019
MIFTS: 33

Cytogenetically Normal Acute Myeloid Leukemia

Categories: Blood diseases, Cancer diseases

Aliases & Classifications for Cytogenetically Normal Acute Myeloid Leukemia

MalaCards integrated aliases for Cytogenetically Normal Acute Myeloid Leukemia:

Name: Cytogenetically Normal Acute Myeloid Leukemia 25 71
Acute Myelogenous Leukemia with Normal Karyotype 25
Normal Karyotype Acute Myeloid Leukemia 25
Cn-Aml 25
Nk-Aml 25

Classifications:



External Ids:

UMLS 71 C3839868

Summaries for Cytogenetically Normal Acute Myeloid Leukemia

Genetics Home Reference : 25 Cytogenetically normal acute myeloid leukemia (CN-AML) is one form of a cancer of the blood-forming tissue (bone marrow) called acute myeloid leukemia. In normal bone marrow, early blood cells called hematopoietic stem cells develop into several types of blood cells: white blood cells (leukocytes) that protect the body from infection, red blood cells (erythrocytes) that carry oxygen, and platelets (thrombocytes) that are involved in blood clotting. In acute myeloid leukemia, the bone marrow makes large numbers of abnormal, immature white blood cells called myeloid blasts. Instead of developing into normal white blood cells, the myeloid blasts develop into cancerous leukemia cells. The large number of abnormal cells in the bone marrow interferes with the production of functional white blood cells, red blood cells, and platelets. People with CN-AML have a shortage of all types of mature blood cells: a shortage of white blood cells (leukopenia) leads to increased susceptibility to infections, a low number of red blood cells (anemia) causes fatigue and weakness, and a reduction in the amount of platelets (thrombocytopenia) can result in easy bruising and abnormal bleeding. Other symptoms of CN-AML may include fever and weight loss. The age at which CN-AML begins ranges from childhood to late adulthood. CN-AML is said to be an intermediate-risk cancer because the prognosis varies: some affected individuals respond well to normal treatment while others may require stronger treatments. The age at which the condition begins and the prognosis are affected by the specific genetic factors involved in the condition.

MalaCards based summary : Cytogenetically Normal Acute Myeloid Leukemia, also known as acute myelogenous leukemia with normal karyotype, is related to acute myeloblastic leukemia with maturation and leukemia, acute monocytic. An important gene associated with Cytogenetically Normal Acute Myeloid Leukemia is FLT3 (Fms Related Receptor Tyrosine Kinase 3), and among its related pathways/superpathways are Glucose / Energy Metabolism and Peroxisome. The drugs Immunoglobulins and Antibodies have been mentioned in the context of this disorder. Affiliated tissues include myeloid, bone marrow and bone, and related phenotypes are Decreased shRNA abundance (Z-score < -2) and Decreased shRNA abundance (Z-score < -2)

Related Diseases for Cytogenetically Normal Acute Myeloid Leukemia

Diseases related to Cytogenetically Normal Acute Myeloid Leukemia via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 89)
# Related Disease Score Top Affiliating Genes
1 acute myeloblastic leukemia with maturation 30.4 NPM1 FLT3
2 leukemia, acute monocytic 30.1 KMT2A FLT3
3 leukemia 29.5 WT1 NPM1 KMT2A FLT3 CEBPA
4 hematologic cancer 29.3 WT1 NPM1 KMT2A FLT3
5 wilms tumor 1 29.2 WT1 NPM1 KMT2A FLT3 CEBPA
6 acute leukemia 29.0 WT1 NPM1 KMT2A FLT3 CEBPA
7 myeloid leukemia 28.7 WT1 NPM1 KMT2A IDH2 IDH1 FLT3
8 leukemia, acute myeloid 28.7 WT1 NPM1 KMT2A IDH2 IDH1 FLT3
9 acute promyelocytic leukemia 28.6 WT1 NPM1 KMT2A FLT3 CEBPA
10 myelodysplastic syndrome 27.4 WT1 NPM1 KMT2A IDH2 IDH1 FLT3
11 wilms tumor 5 10.5
12 acute myeloblastic leukemia without maturation 10.2 NPM1 FLT3
13 acute myeloid leukemia with abnormal bone marrow eosinophils inv(16)(p13q22) or t(16;16)(p13;q22) 10.2 KMT2A FLT3
14 myelodysplastic/myeloproliferative neoplasm 10.1 KMT2A FLT3
15 acute myeloid leukemia with t(8;21)(q22;q22) translocation 10.1 FLT3 CEBPA
16 polykaryocytosis inducer 10.1
17 exanthem 10.1
18 pancytopenia 10.1
19 cholestasis 10.1
20 agammaglobulinemia 10.1
21 b-cell lymphoma 10.1
22 hodgkin's lymphoma, lymphocytic-histiocytic predominance 10.1
23 mast-cell leukemia 10.1
24 acute sensory ataxic neuropathy 10.1
25 acute mast cell leukemia 10.1
26 leukemia, acute lymphoblastic 3 10.0 KMT2A FLT3
27 meningioma, radiation-induced 10.0
28 meningioma, familial 10.0
29 graft-versus-host disease 10.0
30 spinal meningioma 10.0
31 patau syndrome 10.0
32 secretory meningioma 10.0
33 lymphoplasmacyte-rich meningioma 10.0
34 severe combined immunodeficiency 10.0
35 monocytic leukemia 10.0
36 47,xyy 10.0
37 acute monoblastic leukemia 10.0
38 blastic plasmacytoid dendritic cell 10.0
39 chromosomal triplication 10.0
40 dendritic cell tumor 10.0
41 chronic eosinophilic leukemia 10.0 WT1 FLT3
42 mixed phenotype acute leukemia 10.0 WT1 KMT2A
43 chronic leukemia 9.9 WT1 FLT3
44 myeloid sarcoma 9.9 NPM1 KMT2A FLT3
45 precursor t-cell acute lymphoblastic leukemia 9.9 KMT2A FLT3
46 chronic myelomonocytic leukemia 9.8 NPM1 KMT2A FLT3
47 breast intraductal papillomatosis 9.8 IDH2 IDH1
48 intraductal papilloma 9.8 IDH2 IDH1
49 breast duct papilloma 9.8 IDH2 IDH1
50 breast papillomatosis 9.8 IDH2 IDH1

Graphical network of the top 20 diseases related to Cytogenetically Normal Acute Myeloid Leukemia:



Diseases related to Cytogenetically Normal Acute Myeloid Leukemia

Symptoms & Phenotypes for Cytogenetically Normal Acute Myeloid Leukemia

GenomeRNAi Phenotypes related to Cytogenetically Normal Acute Myeloid Leukemia according to GeneCards Suite gene sharing:

26 (show all 31)
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased shRNA abundance (Z-score < -2) GR00366-A-102 9.91 FLT3
2 Decreased shRNA abundance (Z-score < -2) GR00366-A-120 9.91 FLT3
3 Decreased shRNA abundance (Z-score < -2) GR00366-A-121 9.91 CEBPA FLT3
4 Decreased shRNA abundance (Z-score < -2) GR00366-A-122 9.91 CEBPA FLT3
5 Decreased shRNA abundance (Z-score < -2) GR00366-A-123 9.91 FLT3
6 Decreased shRNA abundance (Z-score < -2) GR00366-A-145 9.91 CEBPA FLT3
7 Decreased shRNA abundance (Z-score < -2) GR00366-A-148 9.91 CEBPA
8 Decreased shRNA abundance (Z-score < -2) GR00366-A-163 9.91 FLT3
9 Decreased shRNA abundance (Z-score < -2) GR00366-A-171 9.91 FLT3
10 Decreased shRNA abundance (Z-score < -2) GR00366-A-187 9.91 FLT3
11 Decreased shRNA abundance (Z-score < -2) GR00366-A-204 9.91 CEBPA
12 Decreased shRNA abundance (Z-score < -2) GR00366-A-23 9.91 WT1
13 Decreased shRNA abundance (Z-score < -2) GR00366-A-35 9.91 WT1
14 Decreased shRNA abundance (Z-score < -2) GR00366-A-43 9.91 CEBPA
15 Decreased shRNA abundance (Z-score < -2) GR00366-A-85 9.91 CEBPA
16 Increased shRNA abundance (Z-score > 2) GR00366-A-100 9.53 WT1
17 Increased shRNA abundance (Z-score > 2) GR00366-A-115 9.53 FLT3
18 Increased shRNA abundance (Z-score > 2) GR00366-A-116 9.53 FLT3
19 Increased shRNA abundance (Z-score > 2) GR00366-A-122 9.53 WT1
20 Increased shRNA abundance (Z-score > 2) GR00366-A-145 9.53 WT1
21 Increased shRNA abundance (Z-score > 2) GR00366-A-152 9.53 WT1
22 Increased shRNA abundance (Z-score > 2) GR00366-A-180 9.53 FLT3
23 Increased shRNA abundance (Z-score > 2) GR00366-A-214 9.53 WT1
24 Increased shRNA abundance (Z-score > 2) GR00366-A-25 9.53 FLT3
25 Increased shRNA abundance (Z-score > 2) GR00366-A-30 9.53 WT1
26 Increased shRNA abundance (Z-score > 2) GR00366-A-43 9.53 WT1
27 Increased shRNA abundance (Z-score > 2) GR00366-A-47 9.53 WT1
28 Increased shRNA abundance (Z-score > 2) GR00366-A-48 9.53 CEBPA
29 Increased shRNA abundance (Z-score > 2) GR00366-A-70 9.53 FLT3
30 Increased shRNA abundance (Z-score > 2) GR00366-A-72 9.53 CEBPA
31 Increased shRNA abundance (Z-score > 2) GR00366-A-85 9.53 WT1

MGI Mouse Phenotypes related to Cytogenetically Normal Acute Myeloid Leukemia:

45
# Description MGI Source Accession Score Top Affiliating Genes
1 growth/size/body region MP:0005378 9.8 CEBPA FLT3 IDH1 KMT2A NPM1 WT1
2 hematopoietic system MP:0005397 9.73 CEBPA FLT3 IDH1 KMT2A NPM1 WT1
3 immune system MP:0005387 9.63 CEBPA FLT3 IDH1 KMT2A NPM1 WT1
4 neoplasm MP:0002006 9.43 CEBPA FLT3 IDH2 KMT2A NPM1 WT1
5 no phenotypic analysis MP:0003012 8.92 CEBPA FLT3 KMT2A WT1

Drugs & Therapeutics for Cytogenetically Normal Acute Myeloid Leukemia

Drugs for Cytogenetically Normal Acute Myeloid Leukemia (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):


# Name Status Phase Clinical Trials Cas Number PubChem Id
1 Immunoglobulins
2 Antibodies
3 Antibodies, Monoclonal

Interventional clinical trials:


# Name Status NCT ID Phase Drugs
1 Genome-wide Pharmacogenetic Candidate Gene SNP Array-based Approach to Predict Chemoresponse and Survival in Patients With Acute Myeloid Leukemia With Normal Karyotype Unknown status NCT01066338
2 Relationship Between Immunophenotyping and X-inactive Specific Transcript (Xist) Gene in Acute Myeloid Leukemia Not yet recruiting NCT04288739

Search NIH Clinical Center for Cytogenetically Normal Acute Myeloid Leukemia

Genetic Tests for Cytogenetically Normal Acute Myeloid Leukemia

Anatomical Context for Cytogenetically Normal Acute Myeloid Leukemia

MalaCards organs/tissues related to Cytogenetically Normal Acute Myeloid Leukemia:

40
Myeloid, Bone Marrow, Bone, T Cells, Brain, Testes, Monocytes

Publications for Cytogenetically Normal Acute Myeloid Leukemia

Articles related to Cytogenetically Normal Acute Myeloid Leukemia:

(show top 50) (show all 238)
# Title Authors PMID Year
1
Clinical features and prognosis of normal karyotype acute myeloid leukemia pediatric patients with WT1 mutations: an analysis based on TCGA database. 61
32019476 2020
2
Impact of FLT3-ITD allele ratio and ITD length on therapeutic outcome in cytogenetically normal AML patients without NPM1 mutation. 61
31645666 2020
3
1H, 13C, and 15N Backbone assignments of the human brain and acute leukemia cytoplasmic (BAALC) protein. 61
32240523 2020
4
Epigenetic landscape analysis of lncRNAs in acute myeloid leukemia with DNMT3A mutations. 61
32355762 2020
5
Prognostic relevance of a blastic plasmacytoid dendritic cell neoplasm-like immunophenotype in cytogenetically normal acute myeloid leukemia patients. 61
32186422 2020
6
A 6-Membrane Protein Gene score for prognostic prediction of cytogenetically normal acute myeloid leukemia in multiple cohorts. 61
31892991 2020
7
Prognostic value of CD25/CD123 pattern of expression in acute myeloid leukemia patients with normal cytogenetic. 61
32514390 2020
8
Clinical and functional significance of circular RNAs in cytogenetically normal AML. 61
31945158 2020
9
A Novel Scoring System for Risk Assessment of Elderly Patients With Cytogenetically Normal Acute Myeloid Leukemia Based on Expression of Three AQP1 DNA Methylation-Associated Genes. 61
32373535 2020
10
Identification of STAB1 in Multiple Datasets as a Prognostic Factor for Cytogenetically Normal AML: Mechanism and Drug Indications. 61
31670197 2019
11
Genetic Characterization and Prognostic Relevance of Acquired Uniparental Disomies in Cytogenetically Normal Acute Myeloid Leukemia. 61
31375516 2019
12
The Prognostic Significance of PDE7B in Cytogenetically Normal Acute Myeloid Leukemia. 61
31740742 2019
13
Prognostic and Biologic Relevance of Clinically Applicable Long Noncoding RNA Profiling in Older Patients with Cytogenetically Normal Acute Myeloid Leukemia. 61
31164409 2019
14
[Characterization of mutational pattern of patients with core-binding factor acute myeloid leukemia]. 61
31302905 2019
15
Hepatic leukemia factor is a novel leukemic stem cell regulator in DNMT3A, NPM1, and FLT3-ITD triple-mutated AML. 61
31076446 2019
16
Characterization of acute myeloid leukemia with del(9q) - Impact of the genes in the minimally deleted region. 61
30476680 2019
17
High EGFL7 expression may predict poor prognosis in acute myeloid leukemia patients undergoing allogeneic hematopoietic stem cell transplantation. 61
31306053 2019
18
Overexpression of indoleamine 2,3-dioxygenase correlates with regulatory T cell phenotype in acute myeloid leukemia patients with normal karyotype. 61
30588466 2018
19
A novel type of NPM1 mutation characterized by multiple internal tandem repeats in a case of cytogenetically normal acute myeloid leukemia. 61
29903763 2018
20
Mutant NPM1 Maintains the Leukemic State through HOX Expression. 61
30205049 2018
21
TET2 expression is a potential prognostic and predictive biomarker in cytogenetically normal acute myeloid leukemia. 61
29219176 2018
22
Mutation profile and associated clinical features in Chinese patients with cytogenetically normal acute myeloid leukemia. 61
29573577 2018
23
Lower expression of bone marrow miR-122 is an independent risk factor for overall survival in cytogenetically normal acute myeloid leukemia. 61
29627222 2018
24
Successful Treatment of Cytogenetically Normal Acute Myeloid Leukemia With Ten-Eleven Translocation 2-Isocitrate Dehydrogenase 2 and Additional Sex Comb-like 1-Nucleophosmin Co-mutations by HLA Haploidentical Stem Cell Transplantation: A Case Report and Literature Review. 61
29661468 2018
25
Evolution of Cytogenetically Normal Acute Myeloid Leukemia During Therapy and Relapse: An Exome Sequencing Study of 50 Patients. 61
29330206 2018
26
MiR-362-5p as a novel prognostic predictor of cytogenetically normal acute myeloid leukemia. 61
29540187 2018
27
High Expression of TET1 Predicts Poor Survival in Cytogenetically Normal Acute Myeloid Leukemia From Two Cohorts. 61
29402726 2018
28
KIT D816V Positive Acute Mast Cell Leukemia Associated with Normal Karyotype Acute Myeloid Leukemia. 61
29670776 2018
29
Up-regulation of regulatory T cells, CD200 and TIM3 expression in cytogenetically normal acute myeloid leukemia. 61
29843224 2018
30
Residual disease detection using targeted parallel sequencing predicts relapse in cytogenetically normal acute myeloid leukemia. 61
28960408 2018
31
Identification of long non-coding RNA competing interactions and biological pathways associated with prognosis in pediatric and adolescent cytogenetically normal acute myeloid leukemia. 61
30181715 2018
32
FMS-Like Tyrosine Kinase 3 (FLT3) and Nucleophosmin 1 (NPM1) in Iranian Adult Acute Myeloid Leukemia Patients with Normal Karyotypes: Mutation Status and Clinical and Laboratory Characteristics. 61
28294102 2017
33
FLT3-ITD, NPM1, and DNMT3A Gene Mutations and Risk Factors in Normal Karyotype Acute Myeloid Leukemia and Myelodysplastic Syndrome Patients in Upper Northern Thailand 61
29172276 2017
34
Long non-coding RNA expression profile in cytogenetically normal acute myeloid leukemia identifies a distinct signature and a new biomarker in NPM1-mutated patients. 61
28679652 2017
35
Meis2 as a critical player in MN1-induced leukemia. 61
28960191 2017
36
KRAS overexpression independent of RAS mutations confers an adverse prognosis in cytogenetically normal acute myeloid leukemia. 61
29029494 2017
37
Phe354Leu Polymorphism of LKB1 Is a Potential Prognostic Factor for Cytogenetically Normal Acute Myeloid Leukemia. 61
28882949 2017
38
Long non-coding RNAs: another brick in the wall of normal karyotype acute myeloid leukemia? 61
28760807 2017
39
Prognostic and biologic significance of long non-coding RNA profiling in younger adults with cytogenetically normal acute myeloid leukemia. 61
28473620 2017
40
High CD200 expression is associated with poor prognosis in cytogenetically normal acute myeloid leukemia, even in FlT3-ITD-/NPM1+ patients. 61
28407515 2017
41
A 3-miRNA signature predicts prognosis of pediatric and adolescent cytogenetically normal acute myeloid leukemia. 61
28473658 2017
42
E-26 Transformation-specific Related Gene Expression and Outcomes in Cytogenetically Normal Acute Myeloid Leukemia: A Meta-analysis. 61
28584213 2017
43
Impact of fludarabine-based induction therapy on outcome of FLT3-/NPM1+ cytogenetically normal acute myeloid leukemia. 61
28076884 2017
44
Low NKD1 expression predicts adverse prognosis in cytogenetically normal acute myeloid leukemia. 61
28443469 2017
45
FLT3 and JAK2 Mutations in Acute Myeloid Leukemia Promote Interchromosomal Homologous Recombination and the Potential for Copy Neutral Loss of Heterozygosity. 61
28108507 2017
46
Gene and protein analysis reveals that p53 pathway is functionally inactivated in cytogenetically normal Acute Myeloid Leukemia and Acute Promyelocytic Leukemia. 61
28340577 2017
47
5-Hydroxymethylcytosine correlates with epigenetic regulatory mutations, but may not have prognostic value in predicting survival in normal karyotype acute myeloid leukemia. 61
28039446 2017
48
ETS-related gene is a novel prognostic factor in childhood acute lymphoblastic leukemia. 61
28123582 2017
49
Association of a cytarabine chemosensitivity related gene expression signature with survival in cytogenetically normal acute myeloid leukemia. 61
27903973 2017
50
Molecular Mutations and Their Cooccurrences in Cytogenetically Normal Acute Myeloid Leukemia. 61
28197208 2017

Variations for Cytogenetically Normal Acute Myeloid Leukemia

Expression for Cytogenetically Normal Acute Myeloid Leukemia

Search GEO for disease gene expression data for Cytogenetically Normal Acute Myeloid Leukemia.

Pathways for Cytogenetically Normal Acute Myeloid Leukemia

Pathways related to Cytogenetically Normal Acute Myeloid Leukemia according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1 11.92 IDH2 IDH1 CEBPA
2 11.24 IDH2 IDH1
3 11.21 WT1 KMT2A FLT3 CEBPA
4 10.98 IDH2 IDH1 FLT3
5
Show member pathways
10.27 IDH2 IDH1

GO Terms for Cytogenetically Normal Acute Myeloid Leukemia

Biological processes related to Cytogenetically Normal Acute Myeloid Leukemia according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 positive regulation of transcription by RNA polymerase II GO:0045944 9.71 WT1 NPM1 KMT2A CEBPA
2 positive regulation of transcription, DNA-templated GO:0045893 9.62 WT1 NPM1 KMT2A CEBPA
3 negative regulation of cell proliferation GO:0008285 9.61 WT1 NPM1 CEBPA
4 tricarboxylic acid cycle GO:0006099 9.37 IDH2 IDH1
5 2-oxoglutarate metabolic process GO:0006103 9.26 IDH2 IDH1
6 NADP metabolic process GO:0006739 9.16 IDH2 IDH1
7 isocitrate metabolic process GO:0006102 8.96 IDH2 IDH1
8 glyoxylate cycle GO:0006097 8.62 IDH2 IDH1

Molecular functions related to Cytogenetically Normal Acute Myeloid Leukemia according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 transcription regulatory region sequence-specific DNA binding GO:0000976 9.54 WT1 KMT2A CEBPA
2 protein homodimerization activity GO:0042803 9.46 NPM1 KMT2A IDH1 CEBPA
3 transcription regulatory region DNA binding GO:0044212 9.43 WT1 KMT2A CEBPA
4 oxidoreductase activity, acting on the CH-OH group of donors, NAD or NADP as acceptor GO:0016616 9.4 IDH2 IDH1
5 NAD binding GO:0051287 9.32 IDH2 IDH1
6 isocitrate dehydrogenase (NADP+) activity GO:0004450 8.96 IDH2 IDH1
7 isocitrate dehydrogenase activity GO:0004448 8.62 IDH2 IDH1

Sources for Cytogenetically Normal Acute Myeloid Leukemia

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....